China Cancer Research
#1 Globally in Cancer Research Quality (Nature Index 2024)
Approved CAR-T Therapies
Most in the world
Lower Treatment Costs
vs. Western countries
Active Clinical Trials
2nd globally after US
World's Most Approved CAR-T Therapies
China has approved over 60 CAR-T cell therapies, far exceeding any other country. These include treatments for blood cancers like leukemia and lymphoma, as well as experimental therapies for solid tumors.
Impact:
Patients have access to cutting-edge immunotherapy at a fraction of Western costs
#1 in Global Cancer Research Quality (Nature Index 2024)
China ranks first worldwide in high-quality cancer research output, surpassing the United States and Europe in peer-reviewed publications and breakthrough discoveries.
Impact:
Establishing China as the global leader in cancer science innovation
CAR-T Therapy Cost Revolution
Chinese CAR-T treatments cost $70,000-$150,000 compared to $400,000+ in the US. This 70% cost reduction makes advanced immunotherapy accessible to millions more patients globally.
Impact:
Making life-saving CAR-T therapy affordable for middle-class patients
Innovative Bispecific Antibodies
China leads in developing bispecific antibodies that target two different cancer markers simultaneously, improving treatment precision and reducing side effects.
Impact:
Next-generation targeted therapies with superior efficacy
AI-Powered Drug Discovery
Chinese researchers use artificial intelligence to identify promising cancer drug compounds 10x faster than traditional methods, accelerating development timelines from years to months.
Impact:
Rapid development of novel cancer treatments
Massive Clinical Trial Infrastructure
China conducts more cancer clinical trials than any country except the US, with over 4,000 active studies offering patients access to experimental treatments.
Impact:
Global patients can access cutting-edge trials in China
Chinese Academy of Medical Sciences Cancer Hospital
Beijing
China's largest and most prestigious cancer center, conducting groundbreaking research in immunotherapy, precision medicine, and surgical innovation.
Key Specialties:
Fudan University Shanghai Cancer Center
Shanghai
Leading research hub for breast cancer, colorectal cancer, and innovative radiotherapy techniques. Partners with global institutions for clinical trials.
Key Specialties:
Sun Yat-sen University Cancer Center
Guangzhou
Pioneer in nasopharyngeal carcinoma research (a cancer common in Asia) and targeted therapy development for rare cancers.
Key Specialties:
Access cutting-edge treatments through Chinese clinical trials (many accept international patients)
CAR-T Therapy for Solid Tumors
Testing next-generation CAR-T cells engineered to penetrate and attack solid tumors like lung, liver, and pancreatic cancers.
Bispecific Antibody for Advanced Lung Cancer
Novel bispecific antibody targeting PD-L1 and VEGF simultaneously for non-small cell lung cancer patients who failed prior immunotherapy.
AI-Designed Targeted Therapy for Liver Cancer
First-in-human trial of an AI-discovered small molecule inhibitor for hepatocellular carcinoma with specific genetic mutations.
Registry-listed trials for China currently tracked in our database, sourced from public trial registries.
